In the MTS assay, compared with oxaliplatin or lobaplatin alone, we observed that 4-OI combined with oxaliplatin or lobaplatin had no difference in the viability of CRC cells of the Nrf2 knockdown (Fig. 7A,B). This evidence concerns the gene NFE2L2 and colorectal carcinoma.